Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE: OMP-59R5 in previously untreated stage IV pancreatic cancer
NCT01647828Phase 2Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Oct 2012
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tarextumab in pancreatic cancer (PC), sponsored by OncoMed Pharmaceuticals. Started Oct 2012; status: completed.
02
Drugs
tarextumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01647828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647828.